Editorial policy
How Northline writes, reviews, and updates GLP-1 and peptide content.
In a medical category, editorial standards are part of product quality. This page explains who writes Northline's educational content, what gets medically reviewed, which sources are prioritized, and how corrections should be handled.
Who writes Northline content
Northline’s public content is produced by the editorial team responsible for the site’s marketing, educational, and care-model pages. The bar is simple: the page should help a patient understand the topic without overstating access, certainty, or outcomes.
Public pages should be written in plain language, but they should still reflect the actual constraints of telehealth, compounded medications, and clinician-led prescribing.
What requires medical review
Any page covering GLP-1 drugs, peptide protocols, drug safety, side effects, compounded medication rules, treatment selection, or monitoring expectations should be medically reviewed before publication or major revision.
Non-clinical pages such as general brand pages may not require the same level of review, but they still should not contradict medically reviewed material elsewhere on the site.
Source hierarchy
Northline should prioritize primary or official sources whenever possible: FDA prescribing information, FDA safety communications, peer-reviewed clinical trials, and official regulatory guidance. Secondary summaries can be useful, but they should not be the only source supporting a clinical or regulatory claim.
This is especially important for semaglutide, tirzepatide, and compounded-drug language, where current FDA policy and labeling can change faster than evergreen marketing copy.
Corrections and updates
Every substantive educational page should carry a visible last-reviewed date. If source material changes in a way that affects safety, eligibility, labeling, or legal status, the page should be updated promptly and the review date should move with it.
If Northline learns that a page is misleading, incomplete, or no longer supported by the best available source material, the page should be corrected directly rather than patched with hidden disclaimers.
Commercial transparency
Educational content can support discovery, but it should not disguise advertising as clinical certainty. Pages should be explicit about what Northline offers today, what is on watch, and which claims depend on future launch readiness or regulatory change.
The same rule applies to internal linking and conversion CTAs: they should help users move to related guides or request updates, not imply that reading the page makes treatment more likely.